ArticleScientific reports2021
Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Secretory carcinoma of the breast: a report of six cases with different immunophenotypes and molecular subtypes.Histopathology · 2026Article
- Seven Shades of Triple Negativity: A Review Unveiling the Low-Grade Spectrum of Breast Cancer.Cancers · 2025Review
- Secretory breast carcinoma: morphologic and molecular heterogeneity with indicators of aggressive potential in a cohort of 29 cases.The journal of pathology. Clinical research · 2025Article
- A rare ER-positive secretory breast carcinoma: diagnostic challenges and surgical treatment.Annals of medicine and surgery (2012) · 2025Article
- Prognostic value of FDG PET/CT in special types of breast cancer with non-favorable histology.Discover oncology · 2025Article
- Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit.Breast cancer research and treatment · 2025Article
- Case Report: Metastasis to pleura and mediastinal lymph nodes from breast secretory carcinoma: 10 years follow-up.Frontiers in oncology · 2025Article
- Dysregulated microRNAs in type 2 diabetes and breast cancer: Potential associated molecular mechanisms.World journal of diabetes · 2024Review
- Secretory Carcinoma of the Breast with Apocrine Differentiation-A Peculiar Entity.Medicina (Kaunas, Lithuania) · 2024Article
- Mastopexy for secretory carcinoma of breast in a young female: a case report.Journal of surgical case reports · 2024Article
- Rare subtypes of triple negative breast cancer: Current understanding and future directions.NPJ breast cancer · 2023Review
- Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features.Diagnostic pathology · 2022Article
- Advancement of secretory breast carcinoma: a narrative review.Annals of translational medicine · 2022Review
- PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.Breast cancer research : BCR · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secretory carcinoma of the breast (SCB) is a rather rare entity of invasive breast cancer, the clinicopathologic characteristics and survival outcomes remain to be elaborated. A retrospective review was conducted in SEER database. A total of 190 SCB patients identified in SEER were eligible for inclusion in the analysis. Median age at diagnosis was 56 years (range 2-96 years). Both sexes and bilateral breast could be affected. Intriguingly, the incidence of SCB tended towards to decreasing in recent decades. Small tumor burden was observed with a mean tumor size of 2.13 cm. In a subgroup with sufficient details, positive staining of estrogen receptor (ER) and progesterone receptor (PR) was 58% and 40%, respectively. The vast majority of patients were of well to moderate differentiation (86.86%) and negative regional lymph nodes involvement (70.71%). Nearly half of the patients took radiotherapy and chemotherapy. Seniors were inclined to have an inferior breast cancer specific survival (BCSS) than their younger counterparts (P = 0.018). Patients underwent breast conserving surgery (BCS) and radiotherapy had much better BCSS than its mastectomy counterparts (P = 0.014). Collectively, SCB is a clinical indolent invasive breast cancer with excellent prognosis. BCS in conjunction with radiotherapy would be a rational alternative for this distinct entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.